Reduction of Microembolism After the Intervention Surgery of Intracranial Aneurysms by Administration of Tirofiban
NCT ID: NCT05841147
Last Updated: 2023-05-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
70 participants
INTERVENTIONAL
2023-04-25
2023-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* Is it safe to inject tirofiban intravenously during interventional treatment of intracranial aneurysms？
* What dose of tirofiban is safe and effective?
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Tirofiban for Reduction of Thromboembolic Events in Endovascular Unruptured Aneurysm Repair
NCT06238115
Tirofiban for the Prevention of Early Neurological Deterioration After Intravenous Thrombolysis in Acute Ischemic Stroke
NCT06587347
One Pass Tirofiban In Management of Ischemic Stroke Thrombectomy In China
NCT04851457
Tirofiban for Patients With intraCranial Artery Stenosis and High-risk Acute Non-disabling Cerebrovascular Events(CHANCE-4）
NCT06319846
Improving Neuroprotective Strategy for Ischemic Stroke Before Endovascular Thrombectomy by Intravenous Tirofiban
NCT07135089
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
The control group: The same dose of normal saline was used instead of tirofiban.
PREVENTION
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
The intervention group
An intravenous bolus (6µg/kg) over a 3 min period and a maintenance dose of 0.1µg/kg/min for 18 hour were used in this group.
Tirofiban
Intravenous administration of tirofiban
The control group
The same dose of normal saline was used instead of tirofiban.
normal saline
Intravenous administration of normal saline
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Tirofiban
Intravenous administration of tirofiban
normal saline
Intravenous administration of normal saline
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Unruptured aneurysm with surgical indications;
* Stent assisted coil embolization treatment was received ;
* The patient was willing to receive intervention treatment.
Exclusion Criteria
* Recent (within 1 year) bleeding symptoms such as gastrointestinal bleeding, clinically significant urinary/reproductive tract bleeding, and skin blueness;
* Dissecting aneurysm, pseudoaneurysm, and bullous aneurysm;
* A known history of coagulation disorders, platelet abnormalities, or thrombocytopenia; 5. Platelet count less than 150 × 109/L；
* A history of major surgical procedures or severe physical trauma within one month;
* Severe uncontrolled hypertension (systolic blood pressure\>160mmHg and/or diastolic blood pressure\>100mmHg);
* Hemorrhagic retinopathy;
* Chronic hemodialysis;
* Renal insufficiency.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Lu Hua
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Lu Hua
Chief physician
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Jiangsu Province Hospital
Nanjing, , China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ANHSI
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.